Terms: = Brain cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK
1084 results:
1. A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases.
Bhusare N; Kumar M
Oncol Res; 2024; 32(5):849-875. PubMed ID: 38686058
[TBL] [Abstract] [Full Text] [Related]
2. The emerging role of fatty acid binding protein 7 (FABP7) in cancers.
George Warren W; Osborn M; Yates A; O'Sullivan SE
Drug Discov Today; 2024 May; 29(5):103980. PubMed ID: 38614160
[TBL] [Abstract] [Full Text] [Related]
3. Phosphoproteomic profiling identifies DNMT1 as a key substrate of beta IV spectrin-dependent erk/MAPK signaling in suppressing angiogenesis.
Flores PC; Ahmed T; Podgorski J; Ortiz HR; Langlais PR; Mythreye K; Lee NY
Biochem Biophys Res Commun; 2024 Jun; 711():149916. PubMed ID: 38613866
[TBL] [Abstract] [Full Text] [Related]
4. has-miR-134-5p inhibits the proliferation and migration of glioma cells by regulating the BDNF/erk signaling pathway.
Guo Z; An P; Hong X
Aging (Albany NY); 2024 Apr; 16(7):6510-6520. PubMed ID: 38579169
[TBL] [Abstract] [Full Text] [Related]
5. Estrogen-receptor status determines differential regulation of α1- and α2-adrenoceptor-mediated cell survival, angiogenesis, and intracellular signaling responses in breast cancer cell lines.
Priyanka HP; Pratap UP; Nair RS; Vasantharekha R; ThyagaRajan S
Med Oncol; 2024 Mar; 41(5):92. PubMed ID: 38526769
[TBL] [Abstract] [Full Text] [Related]
6. Unveiling the role of PYGB in pancreatic cancer: a novel diagnostic biomarker and gene therapy target.
Ren LK; Lu RS; Fei XB; Chen SJ; Liu P; Zhu CH; Wang X; Pan YZ
J Cancer Res Clin Oncol; 2024 Mar; 150(3):127. PubMed ID: 38483604
[TBL] [Abstract] [Full Text] [Related]
7. Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression.
Khan F; Lin Y; Ali H; Pang L; Dunterman M; Hsu WH; Frenis K; Grant Rowe R; Wainwright DA; McCortney K; Billingham LK; Miska J; Horbinski C; Lesniak MS; Chen P
Nat Commun; 2024 Mar; 15(1):1987. PubMed ID: 38443336
[TBL] [Abstract] [Full Text] [Related]
8. AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis.
Oskouian B; Lee JY; Asgharzadeh S; Khan R; Zhang M; Weisbrod JR; Choi YJ; Puri L; Aguilar AE; Zhao P; Saba JD
Oncogene; 2024 Apr; 43(16):1203-1213. PubMed ID: 38413795
[TBL] [Abstract] [Full Text] [Related]
9. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
[TBL] [Abstract] [Full Text] [Related]
10. Integrated bioinformatics approaches and expression assays identified new markers in pituitary adenomas.
Motlagh PE; Jamali E; Karimi N; Eslami S; Sharifi G; Ghafouri-Fard S
Pathol Res Pract; 2024 Mar; 255():155193. PubMed ID: 38364650
[TBL] [Abstract] [Full Text] [Related]
11. Phosphorylation of PBK at Thr9 by CDK5 correlates with invasion of prolactinomas.
Fang Q; Liu C; Nie D; Guo J; Xie W; Zhang Y
CNS Neurosci Ther; 2024 Feb; 30(2):e14629. PubMed ID: 38363020
[TBL] [Abstract] [Full Text] [Related]
12. PTX3 activates POSTN and promotes the progression of glioblastoma via the MAPK/erk signalling axis.
Wang Y; Wang B; Cao W; Xu X
Biochem Biophys Res Commun; 2024 Apr; 703():149665. PubMed ID: 38359612
[TBL] [Abstract] [Full Text] [Related]
13. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
Nie J; Dang S; Zhu R; Lu T; Zhang W
Breast Cancer Res; 2024 Jan; 26(1):19. PubMed ID: 38287441
[TBL] [Abstract] [Full Text] [Related]
14. KRAS is a molecular determinant of platinum responsiveness in glioblastoma.
Zuchegna C; Leone S; Romano A; Porcellini A; Messina S
BMC Cancer; 2024 Jan; 24(1):77. PubMed ID: 38225605
[TBL] [Abstract] [Full Text] [Related]
15. Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics.
Sokolov D; Sharda N; Banerjee A; Denisenko K; Basalious EB; Shukla H; Waddell J; Hamdy NM; Banerjee A
Curr Pharm Des; 2024; 30(1):31-47. PubMed ID: 38151840
[TBL] [Abstract] [Full Text] [Related]
16. The erk inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.
de Sauvage MA; Torrini C; Nieblas-Bedolla E; Summers EJ; Sullivan E; Zhang BS; Batchelor E; Marion B; Yamazawa E; Markson SC; Wakimoto H; Nayyar N; Brastianos PK
Neuro Oncol; 2024 May; 26(5):889-901. PubMed ID: 38134951
[TBL] [Abstract] [Full Text] [Related]
17. Therapeutic potential of natural antisense transcripts and various mechanisms involved for clinical applications and disease prevention.
Ali A; Khatoon A; Shao C; Murtaza B; Tanveer Q; Su Z
RNA Biol; 2024 Jan; 21(1):1-18. PubMed ID: 38090817
[TBL] [Abstract] [Full Text] [Related]
18. Varying the RGD concentration on a hyaluronic acid hydrogel influences dormancy versus proliferation in brain metastatic breast cancer cells.
Goodarzi K; Lane R; Rao SS
J Biomed Mater Res A; 2024 May; 112(5):710-720. PubMed ID: 38018303
[TBL] [Abstract] [Full Text] [Related]
19. brain-derived neurotrophic factor (BDNF) downregulates mRNA levels of suppressor of cancer cell invasion (SCAI) variants in cortical neurons.
Ihara D; Mizukoshi M; Tabuchi A
Genes Cells; 2024 Jan; 29(1):99-105. PubMed ID: 38009531
[TBL] [Abstract] [Full Text] [Related]
20. Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
Fangusaro J; Jones DT; Packer RJ; Gutmann DH; Milde T; Witt O; Mueller S; Fisher MJ; Hansford JR; Tabori U; Hargrave D; Bandopadhayay P
Neuro Oncol; 2024 Jan; 26(1):25-37. PubMed ID: 37944912
[TBL] [Abstract] [Full Text] [Related]
[Next]
